Cholix-derived carriers for oral delivery of heterologous payload

Abstract

The present disclosure provides delivery constructs comprising a carrier coupled to a heterologous payload, wherein coupling of the carrier to the payload can result in transportation of the payload (e.g., a therapeutic payload) into and/or across intact polarized epithelial cells (e.g., epithelial cells of the gut of a mammal). The delivery construct can be part of a pharmaceutical composition that can be orally administered to a subject to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases or autoimmune diseases.

What is claimed is: 
     
         1 . A method comprising administering a carrier-payload complex to a subject, wherein the carrier-payload complex comprises (a) a carrier derived from a Cholix polypeptide comprising a leucine at position 1, coupled to (b) a heterologous payload.